Article
The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer.
The Journal of steroid biochemistry and molecular biology - 1 Jun 1997
Tonetti D A, Jordan V C
Abstract excerpt
During the past 20 years, the hormonal therapy of choice for the treatment of breast cancer has been the antiestrogen, tamoxifen. The use of tamoxifen has been proved to produce a favorable response and survival advantage in patients whose tumors are classified as estrogen receptor-positive (ER+)/progesterone receptor-positive (PR+). Additionally, tamoxifen is the only drug known to reduce the incidence of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.